ADAP News and Press, Adaptimmune Therapeutics plc From 09/09/22

U.K.-based biotech Adaptimmune Therapeutics plc ( NASDAQ: ADAP ) announced new data Friday from its Phase 1 SURPASS trial for anti-cancer agent ADP-A2M4CD8 in patients with solid tumors. The data will be part of a presentation at the European Society for Medical Oncology (ES...

- 44% Objective Response Rate (ORR) with a single dose of ADP-A2M4CD8 in 25 heavily pre-treated patients with late-stage ovarian, urothelial, and head & neck cancers - - Further clinical development planned in ovarian (SURPASS-3), urothelial, and head & neck cancers - - Across all t...

- Event to be held on Friday, September 9 th , at 8 a.m. EDT - Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 25, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will provide an update on its Phase 1 SURPASS trial...

Baillie Gifford’s 13F portfolio value decreased from ~$143B to ~$97.51B this quarter. They increased Spotify and Royalty Pharma while decreasing Cloudflare, Petrobras, BeiGene, CBRE Group, Teladoc, and Peloton Interactive. The top three positions are Moderna, Tesla Motors, ...

Adaptimmune Therapeutics plc (ADAP) Q2 2022 Earnings Conference Call Aug 4, 2022 8:00 AM ET Company Participants Juli Miller - Head-Investor Relations Adrian Rawcliffe - Chief Executive Officer Dennis Williams - Senior Vice President, Late Stage Development G...

Adaptimmune press release ( NASDAQ: ADAP ): Q2 Non-GAAP EPS of -$0.05 beats by $0.24 . Revenue of $5.54M (+78.7% Y/Y) misses by $3.16M . For further details see: Adaptimmune Non-GAAP EPS of -$0.05 beats by $0.24, revenue of $5.54M misses by $3.16M

- Reaffirming financial guidance; Company funded into early 2024 - - ASCO data confirms afami-cel potential for synovial sarcoma; BLA submission on-track for Q4 2022 - - Update from signal-finding Phase 1 SURPASS trial at the September ESMO 2022 Congress - - Quarterly call to be held toda...

Several biotechs involved in gene editing are higher on Wednesday in the aftermath of Roche's ( OTCQX:RHHBY ) blockbuster deal with CAR-T-focused Poseida Therapeutics ( PSTX ) announced earlier today. One of the biggest gainers -- up more than 30% -- is Alaunos The...

Adaptimmune ( NASDAQ: ADAP ) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is -$0.29 (-625.0% Y/Y) and the consensus Revenue Estimate is $8.7M (+180.6% Y/Y). Over the last 3 months, EPS estimates ha...

Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - July 21, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the second quarter ended June 30, 2022, before th...